SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Kunz Pamela L.))
 

Search: (WFRF:(Kunz Pamela L.)) > (2017) > Telotristat Ethyl, ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Kulke, Matthew H.Dana Farber Canc Inst, Boston, MA 02115 USA. (author)

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • 2017
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-315064
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-315064URI
  • https://doi.org/10.1200/JCO.2016.69.2780DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlled phase III study evaluated telotristat ethyl in this setting. Patients and Methods Patients (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog therapy received (1: 1: 1) placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg three times per day orally during a 12-week double-blind treatment period. The primary end point was change from baseline in BM frequency. In an open-label extension, 115 patients subsequently received telotristat ethyl 500 mg. Results Estimated differences in BM frequency per day versus placebo averaged over 12 weeks were -0.81 for telotristat ethyl 250 mg (P < .001) and -0.69 for telotristat ethyl 500 mg (P,.001). At week 12, mean BM frequency reductions per day for placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg were -0.9, -1.7, and -2.1, respectively. Responses, predefined as a BM frequency reduction >= 30% from baseline for >= 50% of the double-blind treatment period, were observed in 20%, 44%, and 42% of patients given placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg, respectively. Both telotristat ethyl dosages significantly reduced mean urinary 5-hydroxyindole acetic acid versus placebo at week 12 (P < .001). Mild nausea and asymptomatic increases in gamma-glutamyl transferase were observed in some patients receiving telotristat ethyl. Follow-up of patients during the open-label extension revealed no new safety signals and suggested sustained BM responses to treatment. Conclusion Among patients with carcinoid syndrome not adequately controlled by somatostatin analogs, treatment with telotristat ethyl was generally safe and well tolerated and resulted in significant reductions in BM frequency and urinary 5-hydroxyindole acetic acid.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Hoersch, DieterZentralklinik Bad Berka, Bad Berka, Germany. (author)
  • Caplin, Martyn E.Royal Free Hosp, London, England. (author)
  • Anthony, Lowell B.Univ Kentucky, Lexington, KY USA. (author)
  • Bergsland, EmilyUniv Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. (author)
  • Öberg, KjellUppsala universitet,Endokrin tumörbiologi(Swepub:uu)kjellob (author)
  • Welin, StaffanUppsala universitet,Institutionen för medicinska vetenskaper(Swepub:uu)stafweli (author)
  • Warner, Richard R. P.Icahn Sch Med Mt Sinai, New York, NY 10029 USA. (author)
  • Lombard-Bohas, CatherineHosp Civils Lyon, Hop Edouard Herriot, Lyon, France. (author)
  • Kunz, Pamela L.Stanford Univ, Palo Alto, CA 94304 USA. (author)
  • Grande, EnriqueHosp Univ Ramon y Cajal, Madrid, Spain. (author)
  • Valle, Juan W.Univ Manchester, Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England. (author)
  • Fleming, DouglasIpsen Biosci, Cambridge, MA USA. (author)
  • Lapuerta, PabloLexicon Pharmaceut, The Woodlands, TX USA. (author)
  • Banks, PhillipLexicon Pharmaceut, The Woodlands, TX USA. (author)
  • Jackson, ShannaLexicon Pharmaceut, The Woodlands, TX USA. (author)
  • Zambrowicz, BrianLexicon Pharmaceut, The Woodlands, TX USA. (author)
  • Sands, Arthur T.Lexicon Pharmaceut, The Woodlands, TX USA. (author)
  • Pavel, MarianneCharite, Berlin, Germany. (author)
  • Dana Farber Canc Inst, Boston, MA 02115 USA.Zentralklinik Bad Berka, Bad Berka, Germany. (creator_code:org_t)

Related titles

  • In:Journal of Clinical Oncology35:1, s. 14-230732-183X1527-7755

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view